###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
CYP1B1 mutations in Spanish patients with primary congenital glaucoma: phenotypic and functional variability
###end article-title 0
###begin p 1
The first two authors contributed equally to this work.
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin title 3
Purpose
###end title 3
###begin p 4
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
To analyze the contributions of cytochrome P4501B1 (CYP1B1) mutations to primary congenital glaucoma (PCG) in Spanish patients.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 111 117 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 339 344 <span type="species:ncbi:9606">human</span>
We analyzed, by polymerase chain reaction (PCR) DNA sequencing, the presence of promoter (-1 to -867) and exon CYP1B1 mutations in 38 unrelated Spanish probands affected by PCG. Functional analysis of nine identified mutations was performed measuring ethoxyresorufin O-deethylation activity and CYP1B1 stability in transiently transfected human embryonic kidney 293T (HEK-293-T) cells.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 944 952 <span type="species:ncbi:9606">Patients</span>
###xml 1142 1150 <span type="species:ncbi:9606">patients</span>
We found a total of 16 different mutations in 13 (34.2%) index cases. The identified mutations included nine missense and three nonsense nucleotide changes, three small deletions, and a short duplication. Eleven probands were compound heterozygotes and two were heterozygotes. Six of the identified mutations were novel (A106D, E173X, F261L, E262X, W341X, and P513_K514del). Mutations T404fsX30 and R355fsX69 were the most prevalent among index cases and were detected in six (23.0%) and three (11.5%) patients, respectively. Functional analysis showed that the three nonsense mutants assayed (E173X, E262X, and W341X) and F261L were null alleles. Of the remaining mutants, four (P52L, G61E, Y81N, and E229K) showed catalytic activities ranging from 20% to 40% of wild-type CYP1B1 and high protein instability. Mutation P400S showed normal catalytic activity and moderate instability. These five mutants were classified as hypomorphic alleles. Patients carrying two null alleles showed severe phenotypes featured by very early PCG onset usually at birth or in the first month of life (0.6+/-0.9 months). Incomplete penetrance was detected in patients carrying hypomorphic alleles.
###end p 8
###begin title 9
Conclusions
###end title 9
###begin p 10
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Our data indicate that approximately one-third of Spanish patients with PCG carry loss-of-function CYP1B1 and show that null alleles are associated with the most severe phenotypes. Hypomorphic alleles may contribute to some cases of incomplete penetrance.
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 590 591 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 505 513 <span type="species:ncbi:9606">children</span>
Primary congenital glaucoma (PCG; OMIM ) is usually transmitted as an autosomal-recessive trait with incomplete penetrance [1,2]. The disease is featured by developmental defects of the trabecular meshwork (TM) and the anterior chamber angle of the eye, which leads to aqueous outflow obstruction, elevated intraocular pressure (IOP), and optic nerve damage [3]. PCG is the most common childhood glaucoma, which is observed in the neonatal or infantile period, and is an important cause of visual loss in children. Parental consanguinity is frequently reported, mainly in Arab populations [4-6]. Its incidence has been reported to range from 1:1250 and 1:2500 births in inbred Slovakian Gypsy [7] and Saudi Arabian populations [2], respectively, to 1:5000 and 1:10000 births in Western countries [8].
###end p 12
###begin p 13
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLC3A</italic>
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLC3B</italic>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLC3C</italic>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 249 249 249 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXC1</italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 373 379 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 575 581 575 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 847 853 847 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 959 960 959 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 998 1000 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1199 1201 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1258 1264 1258 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1355 1357 1355 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 524 532 <span type="species:ncbi:9606">patients</span>
Three PCG loci have been mapped, GLC3A (2p21) [9], GLC3B (1p36) [10], and GLC3C (14q24.3) [11]. To date, only the gene linked to the GLC3A locus, cytochrome P4501B1 (CYP1B1; OMIM ), has been identified [12]. Nonetheless, mutations in myocilin (MYOC;OMIM ) [13,14] and forkhead box C1 (FOXC1; OMIM ) [15] have also been reported in some PCG cases. Although the mutations in CYP1B1 are the main known genetic cause of this type of glaucoma [16] in different worldwide populations [4,6,17-22], the role of this gene in Spanish patients has not yet been investigated. Ninety-two CYP1B1 mutations have now been implicated in the pathogenesis of PCG including missense, nonsense, frameshift mutations, and small insertions and deletions (the  professional release 8.1). Most missense mutations map to highly conserved functional regions of the protein. CYP1B1 mutations are also present in certain families where PCG and primary open-angle glaucoma (POAG) coexist [5,21,23], in non-Mendelian POAG cases [24-26], and in monogenic anterior segment dysgenesis like Peters' anomaly [27,28] and Rieger's anomaly [29]. This gene has also been reported to act as a modifier gene in juvenile open-angle glaucoma [30]. The wide range of glaucoma phenotypes associated with CYP1B1 mutations suggests that it plays a key role in the physiology and development of the eye [31].
###end p 13
###begin p 14
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 606 612 606 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
CYP1B1 encodes a member of the cytochrome P450 superfamily, subfamily I, and is composed of three exons with the translated region beginning at the 5' end of the second exon. The CYP1B1 protein is a membrane-bound monomeric mixed function monooxygenase. This cytochrome has been proposed to participate in iridocorneal angle development [32], thus alteration of CYP1B1 catalytic activity could impair the morphogenesis of the outflow angle, leading to IOP elevation and glaucoma. In fact, partial loss-of-function, reduced stability, and diminished localization in the mitochondria have been described for CYP1B1 mutations by a few previous functional reports [6,33-35].
###end p 14
###begin p 15
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 499 505 499 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
We have herein investigated for the first time the role of CYP1B1 mutations in a group of 38 unrelated Spanish families with PCG. We found 16 different loss-of-function CYP1B1 mutations present in approximately one-third of the index cases. Our data show that complete loss of CYP1B1 catalytic activity is associated with the most severe phenotypes and indicate the influence of modifier genes and/or environmental factors in the phenotypic expression, particularly in subjects carrying hypomorphic CYP1B1 alleles.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Subjects
###end title 17
###begin p 18
###xml 1917 1923 1917 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">Patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 499 504 <span type="species:ncbi:9606">Human</span>
###xml 1538 1543 <span type="species:ncbi:9606">child</span>
###xml 1705 1713 <span type="species:ncbi:9606">children</span>
###xml 1830 1838 <span type="species:ncbi:9606">patients</span>
###xml 1952 1960 <span type="species:ncbi:9606">patients</span>
A total of 39 patients (69 eyes) with PCG from 38 different families were recruited for genetic analysis. Thirty-eight patients were Spanish natives with Spanish family names, although the father of one of the index cases (PCG 41) was German. Patients with pediatric glaucoma, which was either related to other ocular disorders or associated with systemic abnormalities, were excluded. In addition, 70 unaffected patients' relatives were studied. The study was approved by the Ethics Committees for Human Research of the hospitals involved (Hospital General Universitario de Alicante, Alicante, Spain, Hospital San Carlos, Madrid, Spain, Hospital La Paz, Madrid, Spain, and Fundacion Jimenez Diaz, Madrid, Spain) and followed the tenets of the Declaration of Helsinki. Informed consents were obtained from all subjects included in the study. Clinical data were retrospectively reviewed. All subjects were clinically evaluated by glaucoma specialists. The ophthalmic examination included slit lamp biomicroscopy, gonioscopy, measurement of IOP and ophthalmoscopy. The clinical diagnosis included at least two of the following clinical features: increased corneal diameter (>12 mm) along with elevated IOP (>21 mmHg or >16 mmHg under general anesthesia) and/or Haab's striae, corneal edema, and optic disc changes. The age at diagnosis ranged from 0 to 28.5 months, although in one case the diagnosis was delayed. Intraocular pressure was measured using the Perkins applanation tonometer generally under halothane anesthesia as soon as the child was sufficiently anesthetized to check intraocular pressure (during the first 10 min after induction and before tracheal intubation). Older and more cooperative children were assessed using a slit lamp for tonometry with a Goldman applanation tonometer. A control group composed of 325 patients from whom glaucoma was ruled out was used to screen for the presence of novel CYP1B1 mutations identified in PCG patients. These subjects were recruited from among those who attended the clinic for conditions other than glaucoma including cataracts, floaters, refractive errors, and itchy eyes.
###end p 18
###begin title 19
Mutation analysis
###end title 19
###begin p 20
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
Genomic DNA was extracted from the peripheral leukocytes of all the subjects studied using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The translated (exons II and III), untranslated (exon I), and promoter (nucleotides -1 to -867) regions of CYP1B1 were amplified as previously described [26]. Terminator cycle sequencing was performed using the BigDye (v3.1) kit (Applied Biosystems, Foster City, CA), and the products of sequencing reactions were analyzed in an automated capillary DNA sequencer (ABI Prism 3130 genetic analyzer; Applied Biosystems). Mutations were confirmed by sequencing the cDNA strand and by independent sequencing in a second DNA sample. The haplotypes for the four SNPs (R48G, A119S, V432L, and N453S) were determined by segregation analysis.
###end p 20
###begin title 21
Site-directed mutagenesis
###end title 21
###begin p 22
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 359 366 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
The cDNA encoding wild-type CYP1B1 was obtained from Invitrogen (cDNA clone ID 4662252; Carlsbad, CA) and was used as a template to produce different CYP1B1 mutations found in PCG patients using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The specific polymerase chain reaction (PCR) primers used for mutagenesis are presented in Table 1. The background haplotype of the wild-type cDNA clone for the four common coding SNPs (R48G, A119S, V432L, and N453S) was RAVN. Therefore, this was the background haplotype of all the cloned mutations. The cDNAs encoding the wild-type protein and the different mutant CYP1B1 forms were cloned into the Xba-BamHI sites of the pcDNA3.1-myc-His mammalian expression vector as previously described [36].
###end p 22
###begin title 23
Primer sequences used in this study.
###end title 23
###begin p 24
In the "Primer sequence" column, "F" indicates forward primer and "R" indicated reverse primer.
###end p 24
###begin title 25
Cell transfections
###end title 25
###begin p 26
###xml 340 341 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 516 518 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 599 606 593 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 730 747 724 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aequorea victoria</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 221 227 <span type="species:ncbi:9913">bovine</span>
###xml 730 747 <span type="species:ncbi:6100">Aequorea victoria</span>
The human embryonic kidney 293T (HEK-293T) cell line was obtained from the  (American type Culture Collection, Manassas, VA), and it was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin and streptomycin; Invitrogen) at 37 degreesC in a fully humidified 5% CO2 atmosphere. Transient plasmid transfections were performed with 400 ng of total DNA using the Superfect Transfection Reagent (Quiagen, Valencia, CA) as previously described [37]. To assess transfection efficiency, the cDNA constructs encoding the different CYP1B1 mutants were cotransfected with 200 ng of a cDNA construct encoding the green fluorescent protein (GFP) from the jellyfish, Aequorea victoria. The GFP cDNA was cloned into the pcDNA3.1 vector. GFP was detected by western blot using an anti-GFP monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
###end p 26
###begin title 27
CYP1B1 enzymatic assay
###end title 27
###begin p 28
###xml 415 417 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
The time course of CYP1B1 activity was analyzed by determining the ethoxyresorufin O-deethylation (EROD) activity in transfected HEK-293T cells. 7-Ethoxiresorufin substrate (400 nM) dissolved in PBS was added to cells in culture 13-15 h after transfection. After 2 h at 37 degreesC, the reaction product (resorufin) that secreted into the culture medium was measured in triplicate aliquots by a fluorometric assay [38] using a SpectraMax(R) GEMINI XS spectrofluorometer (Molecular Devices Corp, Sunnyvale, CA) at 530 nm (excitation) and 590 nm (emission). Endogenous CYP1B1 activity was estimated in control assays performed in HEK-293T cells transiently transfected with the non-recombinant pcDNA3.1 vector. The background activity was subtracted from all the enzymatic assays performed either with wild-type or mutant CYP1B1. Three independent assays for each mutant were performed.
###end p 28
###begin title 29
CYP1B1 stability assay
###end title 29
###begin p 30
###xml 889 894 <span type="species:ncbi:10090">mouse</span>
###xml 1004 1015 <span type="species:ncbi:3704">horseradish</span>
###xml 1055 1060 <span type="species:ncbi:10090">mouse</span>
Protein stability was studied by western blot of transfected cells incubated with cycloheximide (10 microg/ml) for 0 h, 2 h, 5 h, and 8 h. Cycloheximide was added 13-15 h after transfection. After cycloheximide treatment, adhered cells were washed twice with 1 ml of DMEM followed by an addition of 200 microl of lysis buffer containing proteinase inhibitors. Collected cells were vortexed for 30 s at the maximum speed, incubated for 30 min on ice, and sonicated for 10 s (cycle 0.5 s). Aliquots of cell lysates were treated with loading buffer containing beta-mercaptoethanol, boiled for 10 min, and fractionated by SDS-PAGE. Analytical 10% PAGE in the presence of SDS was performed using the Mini-PROTEAN III gel electrophoresis system (Bio-Rad, Hercules, CA). Gels were transferred onto Hybond ECL nitrocellulose membranes (Amersham, Uppsala, Sweden) for immunodetection. A commercial mouse monoclonal anti-myc antibody (Santa Cruz Biotechnology) was used as the primary antibody diluted at 1:500. A horseradish peroxidase-conjugated antibody against mouse IgG (Pierce Biotechnology, Rockford, IL) was diluted at 1:1000. Chemiluminescence detection was performed with Supersignal Dura Western Blot reagents (Pierce). The data from triplicate independent experiments were obtained. The amount of CYP1B1 protein was determined by densitometry, and the relative amounts at the different time points were expressed as a percentage of levels at time 0 h.
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Significance of the difference in age and IOP among patients was determined by the t-test. Data were statistically analyzed by using SigmaStat 2.0 software (SPSS Inc., Chicago, IL).
###end p 32
###begin title 33
Mutation nomenclature
###end title 33
###begin p 34
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
Mutations were named based on the cDNA reference sequence  [39]. The first nucleotide of the transcription initiation site is denoted as nucleotide +1 according to Tang and coworkers [40].
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Clinical phenotype of patients
###end title 36
###begin p 37
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 549 556 <span type="species:ncbi:9606">patient</span>
To investigate the role of CYP1B1 mutations in the development of PCG in Spanish patients, we retrospectively studied a total of 38 unrelated families affected by the disease. PCG segregated as an autosomal recessive trait in 37 families and showed a dominant or pseudo-dominant pattern in one family (PCG 35). Twenty-eight patients (72%) were male, and 11 patients (28%) were female. The disease was bilateral in 30 patients (77%). At the time of diagnosis, ages ranged from 1 day to 36 months (median 6.5 months). The diagnosis was delayed in one patient (PCG 44). Suspicion of primary congenital glaucoma was based on cornea enlargement (100%) and associated hazy corneas (80%), photophobia and blepharospasm (72%), and tearing (64%). Horizontal corneal diameters, measured under general anesthesia, ranged from 12 to 15 mm with an average of 13.25 +/-0.9 mm. The mean preoperative intraocular pressure before the first surgical intervention was 25.4+/-7.1 mmHg. The average cup/disc size ratio was 0.36+/-1.2. Goniotomy was performed as the initial surgical procedure in 29 eyes (42%), combined trabeculotomy-trabeculectomy in 17 eyes (24.6%), trabeculectomy in seven eyes (10%), trabeculotomy in six eyes (8.7%), and surgical data were not available for eight eyes (11.6%). Forty-two eyes (60.8%) needed more than one surgery, and eight eyes (11.5%) required the implantation of the Ahmed valve.
###end p 37
###begin title 38
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Analysis of CYP1B1 mutations
###end title 38
###begin p 39
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 512 519 512 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 524 532 524 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 729 736 729 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 741 749 741 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1125 1132 1125 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 1249 1256 1249 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 1261 1269 1261 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1389 1397 1389 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1554 1560 1554 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1637 1644 1637 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 117 123 <span type="species:ncbi:9606">people</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
Mutations in the promoter region and the three exons of CYP1B1 were analyzed by direct PCR sequencing in a total 109 people, which consisted of 39 affected by PCG and 70 unaffected relatives of the patients. No mutations segregating with the disease were found in the promoter region. We identified a total of 16 distinct DNA mutations in 13 (34.2%) of the 38 unrelated index cases: six transitions (2 G>A and 4 C>T), six transversions (3 C>A, 1 T>A and 2 G>T), three small deletions, and one small duplication (Table 2 and Figure 1). The transitions and transversions predicted nine missense (P52L, G61E, Y81N, A106D, F261L, R390S, P400S, P437L, and R469W) and three nonsense (E262X, W341X, and E173X) amino acid substitutions (Table 2 and Figure 1). On the other hand, the conceptual translation of one nucleotide long and 13 nucleotide long deletions (c.906delG and c.1435_1447delGAGTGCAGGCAGA, respectively) as well as one 10 nucleotide long duplication (c.1571_1580dupTCATGCCACC) resulted in three frameshift mutations followed by stop codons in the new reading frame (A179fsX18, T404fsX30, and R355fsX69, respectively; Table 2). Besides, the six nucleotide long deletion (c.907_912delACCCAA) predicted a two amino acid deletion, K513_P514del (Table 2 and Figure 1). To the best of our knowledge, 6 of the 14 mutations were novel (A106D, E173X, F261L, E262X, W341X, and K513_P514del; Figure 1). None of these six novel mutations was found in 325 (650 chromosomes) unrelated control subjects. The highest allelic frequency among PCG index cases with CYP1B1 mutations corresponded to mutations T404fsX30 (23.0%) and R355fsX69 (11.5%; Table 2).
###end p 39
###begin title 40
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
CYP1B1 mutations identified in Spanish PCG patients.
###end title 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 263 269 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 281 282 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
###xml 461 462 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</sup>
###xml 471 472 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sup>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sup>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
aMutations were named based on cDNA reference sequence  [39]. The first nucleotide of the transcription initiation site is denoted as nucleotide +1 according to Tang and coworkers [40]. bThe data from this column are the allelic frequency among PCG probands with CYP1B1 mutations. cThe haplotypes are for the four common coding SNPs (R48G, A119S, V432L and N453S). These mutations have been described as follows: d3987G>A; e4046T>A; f1410-1422delGAGTGCAGGCAGA; g1514C>A; hc.1198C>T; i1546-1555dupTCATGCCACC; and j1656C>T; k1751C>T.
###end p 41
###begin p 42
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 147 148 147 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 159 160 159 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 170 171 170 171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 194 195 194 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 210 211 210 211 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
Detection of six novel CYP1B1 mutations in Spanish PCG families by direct PCR DNA sequencing. Sequencing results of probands from families PCG 45 (A), PCG 28 (B), PCG 1 (C), PCG 29 (D), PCG 34 (E), and PCG 32 (F). Control electropherograms are shown for comparison purposes. The arrows indicate the position of mutations.
###end p 42
###begin p 43
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 372 380 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 604 612 604 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 702 710 702 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 896 897 896 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 898 899 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 730 738 <span type="species:ncbi:9606">patients</span>
Most of these mutations were found in compound heterozygous subjects (85.7%). Nonetheless, we identified two index cases (14.3%) that were heterozygous for mutations P52L and Y81N (families PCG 3 and PCG 4, respectively; Figure 2). In contrast and as expected, relatives of these two patients who were heterozygotes for mutations Y81N and P52L were phenotypically normal (Figure 2). An intriguing finding was that three compound heterozygotes did not show any type of glaucoma at the time of the study. Two of them were siblings carrying mutations P52L and E229K (family PCG 3, subjects III:1 and III:2; Figure 2) while the third relative carried mutations E229K and R469W (family PCG 25, subject I:1; Figure 2). The age of these patients at the time of the study ranged from 28 to 58 years. Therefore, they likely represent cases of incomplete penetrance, which has been well documented in PCG [2,4,12,41]. It is interesting to note that mutation E229K was present in the three cases of incomplete penetrance detected in this study.
###end p 43
###begin p 44
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Pedigrees of PCG Spanish families with CYP1B1 mutations. Genotypes are indicated below the symbols. DNA samples were not available from the parents of probands in families PCG 29, PCG 32, and PCG 34. Therefore, their genotypes could not be determined. Arrows show the probands. Black and gray symbols indicate PCG and OHT phenotypes, respectively. +: wild-type allele.
###end p 44
###begin p 45
###xml 171 179 171 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
Mutations R355fsX69 and F261L were identified in the compound heterozygous state in the index case of family PCG 1 (IV:2) who manifested the disease at the time of birth (Figure 2). These mutations were also present in the heterozygous state in 11 unaffected carriers from the same pedigree. However, the oldest F261L carrier (I:1; 83 years old at the time of the study) was diagnosed with ocular hypertension (OHT) during the study, although we cannot rule out that this finding was merely a coincidence. Similarly, several normal heterozygous carriers of mutations G61E and T404fsX30 were identified in families PCG 2 and PCG 5.
###end p 45
###begin p 46
###xml 128 136 128 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 554 562 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 710 714 710 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 239 244 <span type="species:ncbi:9606">woman</span>
###xml 279 282 <span type="species:ncbi:9606">man</span>
Family PCG 25 also presented two affected siblings who who were compound heterozygotes with the same genotype (R469W/T404fsX30; Figure 2). As previously mentioned, their father could represent a case of incomplete penetrance. The affected woman, II:2, married an unrelated blind man diagnosed with PCG (PCG 25b, Figure 2) who had no mutations in either CYP1B1 or MYOC. Two affected siblings were present in family PCG 29, the index case was a compound heterozygote (E262X/P513_K514del), but we were unable to perform DNA analysis in her affected sister (Figure 2). The index cases from families PCG 32 and PCG 34 were also compound heterozygotes. We ruled out the presence of mutations in the coding region of MYOC in all the families (data not shown).
###end p 46
###begin title 47
Haplotype analysis
###end title 47
###begin p 48
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 271 278 271 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Analysis of 4 coding common CYP1B1 SNPs (R48G, A199S, V432L, and N453S) revealed that RAVN was the most common haplotype (65.6%) among the Spanish patients who carried CYP1B1 mutations. In addition, RAVN was the haplotype background in 10 of the 16 identified mutations (Table 2).
###end p 48
###begin title 49
Evaluation of novel mutated positions by multiple sequence alignment
###end title 49
###begin p 50
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 442 450 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 791 799 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
To evaluate the degree of phylogenetic conservation of the novel mutated amino acid residues and the possible impact of the novel mutations in the structure and function of the protein, we compared the amino acid sequences of some mammalian and fish CYP1B1 enzymes and also two of the mammalian members of the well characterized CYP1A1 and CYP1A2 subfamilies (Figure 3). All the novel mutations affected highly conserved amino acid residues (Figure 3). The three nonsense mutations were predicted to truncate the protein at helices D, G, and I whereas the deletion of two amino acids (P513_K514del) affected the beta 3.2-sheet. These mutations are likely to produce a complete loss-of-function of the protein. The two novel missense mutations were located in helices B (A106D) and G (F261L; Figure 3).
###end p 50
###begin p 51
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 62 63 62 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 284 285 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Location of six novel CYP1B1 mutations found in PCG patients. A: Scheme of the CYP1B1 gene showing the position of the novel mutations identified in this study. The three exons are represented by boxes, and different conserved structural domains encoded by them are depicted in pink. B: Multiple amino acid sequence alignment of CYP1B1, CYP1A1 and CYP1A2 from different species. The three exons are represented by boxes, and different conserved structural domains encoded by them are depicted by different patterns and shadings. Sequence alignment was generated by . Arrows indicate the residues affected by mutations. Different structural domains of the cytochrome P450 superfamily are indicated. Asterisks indicate amino acid positions at which all query sequences are identical. Amino acid positions at which all the analyzed sequences had amino acids that were chemically similar are denoted by two dots (:). One dot denotes amino acid positions with weak chemical similarity (.).
###end p 51
###begin title 52
Functional analysis of CYP1B1 mutations
###end title 52
###begin p 53
###xml 648 657 648 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A</xref>
###xml 930 939 930 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A</xref>
###xml 1127 1136 1127 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4B</xref>
To experimentally assess the effect of the mutations on the function of CYP1B1 and to analyze whether different levels of enzymatic activity correlate with the phenotype, we analyzed their enzymatic activity and protein stability. We were able to clone a total of nine mutations (three of them novel) by site-directed mutagenesis as described in the Methods. CYP1B1 enzymatic activity was estimated by determining the EROD activity in transfected HEK-293T cells with a fluorimetric assay at 2 h after addition of the substrate. Eight mutants showed reduced enzymatic activity compared with the wild-type protein while P400S showed normal activity (Figure 4A). Variants displaying an activity below 1% of the wild-type (E173X, F261L, E262X, and R469W) were classified as null alleles, and those with enzymatic activity ranging from 20% to 40% of wild-type CYP1B1 (P52L, G61E, Y81N, and E229K) were considered hypomorphic variants (Figure 4A). Detection of CYP1B1 in cells by western blot analysis 2 h after the enzymatic assay showed reduced protein levels for the following CYP1B1 mutants: G61E, Y81N, E262X, P400S, and R469W (Figure 4B). GFP analysis showed that there were no significant differences in transfection efficiency. These data indicate that although mutation P400S does not reduce the catalytic activity, it impairs protein stability, likely resulting in reduced enzymatic activity levels over time.
###end p 53
###begin p 54
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 458 459 458 459 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Effect of CYP1B1 mutations found in Spanish PCG patients on CYP1B1 catalytic activity. A: cDNA constructs encoding the different mutations were transiently expressed in HEK-293T cells. Transfection efficiency was assessed by co-transfection with a cDNA construct encoding GFP. The EROD activity, expressed as a percentage of the activity of the wild-type protein, was measured as indicated in Methods. Error bars represent the SEM of triplicate experiments. B: Protein levels of the different CYP1B1 mutants present in transiently transfected HEK-293T cells 2 h after the enzymatic assay are shown as a control of protein expression. CYP1B1 polypeptides, tagged with the myc epitope at their COOH-terminal end, were detected by western immunoblot using a monoclonal anti-myc antibody (Santa Cruz). GFP was detected using an anti-GFP antibody (Santa Cruz).
###end p 54
###begin p 55
###xml 507 515 507 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 722 730 722 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 952 960 952 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
We then specifically investigated the protein stability of these mutants using transiently transfected HEK-293T cells that were treated with the protein synthesis inhibitor, cycloheximide, at various time points. Cells appeared viable upon microscopic examination at the latest time point used (8 h). We observed that the amount of all the CYP1B1 variants decreased upon exposure to cycloheximide, but the degradation of all the mutants was significantly more pronounced than that of the wild-type protein (Figure 5). Eight hours after cycloheximide exposure, the relative amount of wild-type CYP1B1 was 78% of the initial value (Time 0) while the protein level for three mutants was lower than 5% (G61E, Y81N, and E262X; Figure 5). A second group of mutants (P52L and E229K) showed protein levels close to 20% of the initial value. The amount of E173X, P400S, and R469W was around 40% while F261L showed the highest relative value among mutants (55%; Figure 5). Interestingly, although the last mutation did not strongly affect the stability of the polypeptide chain after 8 h of cycloheximide treatment, it completely inactivated the catalytic activity. However, mutation P400S, which did not impair the catalytic activity, significantly reduced the CYP1B1 protein levels to about 35% of the initial value. These data show that the CYP1B1 mutations associated with PCG impair the function of the cytochrome P450 molecule by affecting their catalytic activity and/or protein stability to different extents, thus supporting that different levels of residual CYP1B1 activity might underlie the development of the disease and phenotypic variability.
###end p 55
###begin p 56
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Time course stability of CYP1B1 mutant polypeptides found in Spanish PCG patients. cDNA constructs encoding the different mutations were transiently expressed in HEK-293T cells. Cells were treated with cycloheximide, a protein synthesis inhibitor, and the amount of the different CYP1B1 polypeptides, tagged with the myc epitope at their COOH-terminal ends, were determined by densitometry of the signals detected in western blots using an anti-myc monoclonal antibody (Santa Cruz) at the indicated time points. Transfection efficiency was assessed by co-transfection with a cDNA construct encoding GFP. When required, CYP1B1 protein levels were corrected for transfection efficiency. Relative amounts of CYP1B1 are expressed as a percentage of levels at time 0 h. Error bars represent the SEM of triplicate experiments.
###end p 56
###begin title 57
Genotype-phenotype correlation
###end title 57
###begin p 58
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 193 200 193 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 589 595 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1189 1196 1181 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 1228 1234 1220 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
###xml 947 955 <span type="species:ncbi:9606">patients</span>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
To analyze the genotype-phenotype relationship, we first compared the clinical features between PCG patients who carried CYP1B1 mutations and those with no identified CYP1B1 or MYOC mutations (Table 3). The percentage of bilateral cases, age at diagnosis, and male/female ratio did not differ significantly between the two groups. The mean IOP values in the affected eyes were higher among mutation carriers (26.8+/-7.8 mmHg) than among non-carriers (23.1+/-7.9 mmHg), although the differences were not significant (p=0.083). We then compared clinical parameters between patients with two CYP1B1 null alleles and the rest of the carriers. Interestingly, the first group was of a younger mean age at diagnosis that those who carried at least one hypomorphic allele (0.6+/-0.9 months versus 17.3+/-15.2 months, respectively; p<0.05). Although patients with two null alleles showed higher mean IOP values at diagnosis and higher mean C/D ratios than patients with at least one hypomorphic allele, the differences were not significant. There were no significant differences noted for the three groups of patients with regard to the mean number of filtration surgeries required to control IOP (Table 3). All these data indicate that CYP1B1 null mutations are associated with the severe PCG phenotypes mainly characterized by a very young age at diagnosis.
###end p 58
###begin title 59
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Clinical features of patients with either CYP1B1 mutations or no detected mutations.
###end title 59
###begin p 60
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 600 601 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 618 619 618 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
Visual acuity was evaluated with a Snellen chart. Genotypes combining two CYP1B1 null alleles are indicated in bold. A/HM/LP: amaurosis/hand movements/light perception; B/U: bilateral/unilateral; C/CCE/MSS: clear/chronic corneal edema/mild stromal scarring; CTT/G/T/Tt: combined trabeculotomy-trabeculectomy/goniotomy/trabeculectomy/trabeculotomy; KB/PB: keratopathy in band/peripheral defect; F/M: female/male; ND: not determined; OD/OS: right eye/left eye; UA: unassessable; aIOP under general anesthesia; bincluding Ahmed valve; cpersistent fetal vasculature unrelated to glaucoma; dptisis bulbi; eeviscerated eye; fdelayed diagnosis.
###end p 60
###begin title 61
Discussion
###end title 61
###begin title 62
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
CYP1B1 mutations in primary congenital glaucoma in Spain
###end title 62
###begin p 63
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 1303 1310 1303 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1 </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 831 839 <span type="species:ncbi:9606">patients</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
###xml 1076 1081 <span type="species:ncbi:9606">human</span>
###xml 1240 1245 <span type="species:ncbi:9606">human</span>
###xml 1365 1373 <span type="species:ncbi:9606">patients</span>
Human CYP1B1 has been implicated in primary congenital glaucoma in different human populations. However, the role of this gene in Spanish patients has not yet been investigated, and the number of studies performed in European populations is still low. Here, we report the first molecular and functional analysis of CYP1B1 mutations in Spanish PCG patients. The findings, particularly those arising from functional studies, may have some general implications for understanding the pathogenesis of the disease. Our data show that around 34% of the studied index cases with autosomal recessive PCG carry mutations in this gene. This value is within the range found in groups of patients from different countries, around 10% in Mexico [42] and Ecuador [43]; 20% in Indonesia [17], Australia [18], and Japan [19]; around 40% in Turkish patients [6]; approximately 50% in Brazil [20] and France [21]; and about 100% in consanguineous Saudi Arabian [4] and Slovakian Gypsy [22] patients. These data illustrate that the contribution of defects in this gene varies significantly among human populations, which highlights that analyzing large groups of PCG from different ethnic backgrounds is required to ascertain the role of this gene in specific human groups. We also found an elevated proportion of compound CYP1B1 heterozygosity and allelic heterogeneity among Spanish patients. In this regard, a total of 16 different mutations were identified. To the best of our knowledge six of them were novel.
###end p 63
###begin p 64
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 115 121 <span type="species:ncbi:9103">Turkey</span>
###xml 294 301 <span type="species:ncbi:9606">patient</span>
###xml 645 652 <span type="species:ncbi:9606">patient</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 848 855 <span type="species:ncbi:9606">patient</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
###xml 957 963 <span type="species:ncbi:9103">Turkey</span>
###xml 1084 1092 <span type="species:ncbi:9606">patients</span>
Mutation G61E has been previously identified in PCG patients from Saudi Arabia [2], Morocco [44], Mexico [42], and Turkey [6]. Variant Y81N was identified in Spanish [26] and French [25] POAG cases. Mutation P400S has previously been reported in the homozygous state in only one Australian PCG patient of Indian descent [18]. Interestingly, the father of this Australian PCG case was diagnosed with juvenile onset open-angle glaucoma and was heterozygous for this mutation, thus supporting the pathogenicity of this variant and showing that it is associated with different glaucoma phenotypes. Mutation P52L was initially described in a Spanish patient with POAG and also in a 66-year-old subject who was clinically normal at the time of the study [26]. Recently, it has been found as a loss-of-function mutation in German POAG patients and in one patient with hepatocellular adenoma [45]. Mutation P437L has been reported in PCG patients from Brazil [20], Turkey [12], and India [46]. It is noteworthy that these three PCG mutations (P400S, P52L, and P437L) were previously found in patients with POAG, showing their association with different glaucoma phenotypes.
###end p 64
###begin title 65
Haplotype background
###end title 65
###begin p 66
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
Most of the mutations identified in this study were embedded in the same haplotype (RAVN). It has been reported that founder effects must have occurred for most CYP1B1 mutations [47]. Our data agree with the founder effect hypothesis, but as this haplotype is the most common in the Spanish population, present in 37% of normal subjects (unpublished results), an extended haplotype analysis is required to confirm this hypothesis.
###end p 66
###begin title 67
Phylogenetic and functional analysis
###end title 67
###begin p 68
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
All the novel mutations identified in this study affect highly evolutionary conserved amino acid residues and were predicted either to truncate the protein or to alter the physicochemical properties of the affected amino acids, supporting their pathogenic character. In that sense, mutation A106D changed a non-polar amino acid for a residue with a negative charge while F261L substituted a large and aromatic amino acid for an aliphatic residue. These mutations were located in helices B, D, G, and I and in the beta 3.2-sheet, which are structurally and functionally relevant. Helices B and D are relatively well conserved structurally [48]. The G helix forms part of the substrate access channel [49], and the I-helix of the heme-binding region contains catalytically important residues [49]. The COOH-terminal half of helix I and the beta 3.2-sheet belong to the most structurally conserved regions in cytochrome P450 [48]. Analysis of the EROD enzymatic activity demonstrated a complete loss-of-function of four mutants (E173X, F261L, E262X, and R469W), which clearly demonstrates that they are null alleles. In addition, the null alleles differed in protein stability. E262X was highly unstable while E173X, F261L, and R469W were moderately unstable. As all these mutations result in inactive enzyme variants, it is unlikely that the differences on stability may influence the phenotypic outcome. Most hypomorphic alleles (P52L, G61E, Y81N, and E229K) displayed reduced catalytic activity and protein instability (protein level after 8 h of protein synthesis inhibition less than 20% of the level at the initial time). Nonetheless, P400S showed normal catalytic activity and a significant reduction of protein stability. All these allele-dependent differences in enzymatic activity and protein stability could contribute to explain cases of incomplete penetrance as we will discuss later.
###end p 68
###begin p 69
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1128 1130 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1375 1377 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
Few functional studies of pathogenic CYP1B1 mutations have previously been reported. In accordance with our results, one of these studies found that mutants G61E and R469W have reduced enzymatic activity (50% and 30%, respectively) toward steroid hormones as substrates [33]. Regarding protein stability, Jansson and co-workers performed a study using membrane preparations obtained from bacteria expressing recombinant CYP1B1 mutants [33]. They found that G61E was much less stable than the wild-type protein (the CYP1B1 level decreased about 50%, after 24 h storage at 4 masculineC). Unlike our results, however, they reported that R469W was as stable as the wild type enzyme. This discrepancy could be due to different experimental settings since in the present study we measured CYP1B1 levels in eukaryotic cells after inhibiting protein synthesis with cycloheximide. A second report also classified Y81N and E229K as hypomorphic alleles and proposed that these two sequence variants could function as risk alleles, which can lead to the development of glaucoma in the presence of modifier genes or environmental influence [34]. These two mutations have also been found to reduce protein stability, although while Y81N severely inhibits the turnover of various substrates, E229K impacts the ability to metabolize substrates moderately depending on the type of substrate [35].
###end p 69
###begin title 70
Incomplete penetrance and hypomorphic alleles
###end title 70
###begin p 71
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 655 661 655 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 909 915 909 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 917 918 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 951 957 951 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1051 1057 1051 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 1191 1193 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 1416 1418 1416 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 1510 1516 1510 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1785 1791 1785 1791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1978 1980 1978 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 1981 1983 1981 1983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 1646 1654 <span type="species:ncbi:9606">patients</span>
###xml 1746 1754 <span type="species:ncbi:9606">patients</span>
Incomplete penetrance has been associated with several CYP1B1 mutations including G61E, R368H, D374N, R469W, g.4340delG, C209R, and g.4238del10 [2,4,41]. Interestingly, we observed three compound heterozygotes with incomplete penetrance in families PCG 3 and PCG 25 who carried at least one copy of the hypomorphic alleles P52L or E229K. In accordance with Bejjani and coworkers [4] and as mentioned before, we speculate that residual enzymatic activity from hypomorphic alleles in these subjects could be sufficient to maintain the normal phenotype either alone or in cooperation with compensating variants of unknown modifier genes and/or the increased CYP1B1 expression induced by compounds present in the environment and/or the diet. In line with these ideas, it has also been proposed that reduced penetrance could be due to a dominant suppressor of the PCG phenotype, which is not linked genetically to CYP1B1 [2], and/or to the inducibility of CYP1B1 by environmental lipophilic agents to which individuals may have been exposed [33]. In fact, CYP1B1 is inducible upon activation of the aryl hydrocarbon receptor by the binding of ligands such as polycyclic aromatic hydrocarbons [50,51] and by compounds found in certain vegetables [52]. According to the present results and to our hypothesis, mutation E229K accompanied by c.1064-1076del (likely a null allele) has also been identified in a normal carrier [47]. Incomplete penetrance, particularly although not exclusively associated with hypomorphic CYP1B1 alleles, indicates that PCG is not a simple recessive trait and underscores its multifactorial character at least in a subset of patients. However, the glaucoma phenotype could be less variable and therefore, more predictable in patients who carry completely inactive CYP1B1 alleles. Incomplete penetrance associated with partial loss of protein function originated by structural mutations has also been reported in diseases such as in familial retinoblastoma [53,54].
###end p 71
###begin title 72
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Heterozygous CYP1B1 mutations in primary congenital glaucoma
###end title 72
###begin p 73
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
###xml 871 877 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 882 887 882 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FOXC1</italic>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1135 1141 1135 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 320 327 <span type="species:ncbi:9606">patient</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
###xml 624 631 <span type="species:ncbi:9606">patient</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
Another intriguing finding that apparently does not match a typical recessive pattern of inheritance is the presence of heterozygous CYP1B1 mutations in PCG patients. This situation has been previously reported [35]. According to our data, mutation Y81N in the heterozygous state has also been described in a German PCG patient [47]. Moreover, E229K, R368H, and R469W were reported as the only mutant allele in Turkish PCG patients [6], and E229K has been identified in the heterozygous state in two unrelated French patients affected by PCG [21], in five Indian patients [55], in one Turkish case [6], and in one Caucasian patient [41]. Interestingly, some of these mutations in the heterozygous state are also associated with the milder POAG phenotype in patients from Spain [26], France [25], and India [24,56]. Recently, the presence of double heterozygous variants, CYP1B1 and FOXC1, has been described in two PCG cases, although the role of possible digenism in disease causation is yet to be established [15]. Once again, defective variants of modifier genes and/or environmental compounds could cooperate with loss-of-function CYP1B1 alleles to produce the disease phenotype. However, further work is required to unravel this point.
###end p 73
###begin title 74
Genotype-phenotype correlation
###end title 74
###begin p 75
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1008 1014 1006 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1356 1358 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
###xml 1492 1498 1490 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1551 1553 1549 1551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 614 622 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
###xml 1596 1604 <span type="species:ncbi:9606">patients</span>
Previous studies have reported that the age at diagnosis in PCG patients with CYP1B1 mutations is younger than for patients without mutations [57]. Our data show that although the disease was diagnosed earlier in carriers of CYP1B1 mutations than in non-carriers, the differences found were not significant. We reasoned that patients with two null CYP1B1 alleles, which means there is no CYP1B1 catalytic activity, could present more severe phenotypes than carriers of at least one hypomorphic allele, who likely conserve residual enzymatic activity levels. According to this hypothesis, our results show that PCG patients with a complete loss of CYP1B1 enzymatic activity display the most severe disease phenotype featured by very early mean onset of the disease (0.6+/-0.9 months). We also observed higher mean IOP values and optic disc excavations in this group of patients, but the differences were not statistically significant. In accordance with the idea of associating the worst phenotypes with null CYP1B1 mutations, the percentage of severe phenotypes in at least one eye have been reported to be associated with various mutations ranging from 100% for a frameshift mutation (376insA) producing a truncated protein at codon 223 (null allele) to approximately 62%-83% for different missense mutations such as G61E, P193L, E229K, R368H, and R390C [55]. According to our data, two of these mutations (G61E and E229K) are hypomorphic alleles. Moreover, E229K has been found as the only CYP1B1 allele in a PCG case with moderate goniodysgenesis [41]. Further studies with a larger number of patients will be required to confirm whether in fact the complete absence of CYP1B1 activity correlates with the worst phenotype.
###end p 75
###begin p 76
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
The identification of a panel of 16 different CYP1B1 mutations for the first time in Spanish PCG patients with allele dependent functional heterogeneity could provide a basis to better understanding of the disease as well as to improve genetic testing and genetic PCG counseling. This in turn will contribute to early diagnosis and prevention of blindness, which can result from a late diagnosis of PCG. Hopefully, this will reduce the burden of the afflicted families and will improve their quality of life since it has been shown that early and prompt surgical interventions in PCG patients leads to a better prognosis [58,59]. Finally, our data clearly indicate that other genetic and/or environmental factors remain to be identified, particularly in patients carrying hypomorphic mutations.
###end p 76
###begin title 77
Acknowledgments
###end title 77
###begin p 78
###xml 23 31 <span type="species:ncbi:9606">patients</span>
We are indebted to the patients and their families for their enthusiastic cooperation in this study. We thank Mrs. Mercedes Iniguez de Onzono for technical assistance and the following nurses that contributed to the study by extracting blood samples: Mrs. Maria Alfaro-Aroca, Mrs. Francisca Climent, Mrs. Ana Torregrosa, Mrs. Asuncion Linares, and Mrs. Maria Victoria Avargues. This study was supported in part by research grants PI052494 and 02021-00 from the "Fondo de Investigaciones Sanitarias" and "Consejeria de Sanidad" of the "Junta de Comunidades de Castilla-La Mancha," respectively. We thank Dr. Francisco Sanchez-Sanchez for helpful discussion and critically reading the manuscript. Mrs. Maria-Pilar Lopez-Garrido was recipient of a fellowship from the "Consejeria de Sanidad de la Junta de Comunidades de Castilla-La Mancha."
###end p 78
###begin title 79
References
###end title 79
###begin article-title 80
Congenital glaucoma and its inheritance.
###end article-title 80
###begin article-title 81
Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus.
###end article-title 81
###begin article-title 82
Primary infantile glaucoma (congenital glaucoma).
###end article-title 82
###begin article-title 83
Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia.
###end article-title 83
###begin article-title 84
A novel frameshift founder mutation in the cytochrome P450 1B1 (CYP1B1) gene is associated with primary congenital glaucoma in Morocco.
###end article-title 84
###begin article-title 85
Mutational screening of CYP1B1 in Turkish PCG families and functional analyses of newly detected mutations.
###end article-title 85
###begin article-title 86
Epidemiology and genetics of primary congenital glaucoma in Slovakia. Description of a form of primary congenital glaucoma in gypsies with autosomal-recessive inheritance and complete penetrance.
###end article-title 86
###begin article-title 87
Primary congenital glaucoma: 2004 update.
###end article-title 87
###begin article-title 88
Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity.
###end article-title 88
###begin article-title 89
A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region.
###end article-title 89
###begin article-title 90
Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1.
###end article-title 90
###begin article-title 91
Gln48His is the prevalent myocilin mutation in primary open angle and primary congenital glaucoma phenotypes in India.
###end article-title 91
###begin article-title 92
Myocilin gene implicated in primary congenital glaucoma.
###end article-title 92
###begin article-title 93
The Transcription Factor Gene FOXC1 Exhibits a Limited Role in Primary Congenital Glaucoma.
###end article-title 93
###begin article-title 94
Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21.
###end article-title 94
###begin article-title 95
###xml 79 87 <span type="species:ncbi:9606">patients</span>
CYP1B1 gene analysis in primary congenital glaucoma in Indonesian and European patients.
###end article-title 95
###begin article-title 96
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Prevalence of CYP1B1 mutations in Australian patients with primary congenital glaucoma.
###end article-title 96
###begin article-title 97
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with primary congenital glaucoma.
###end article-title 97
###begin article-title 98
Molecular genetics of primary congenital glaucoma in Brazil.
###end article-title 98
###begin article-title 99
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France.
###end article-title 99
###begin article-title 100
Molecular diagnosis of mutations responsible for recurrent and severe forms of primary congenital glaucoma.
###end article-title 100
###begin article-title 101
Molecular characterisation of congenital glaucoma in a consanguineous Canadian community: a step towards preventing glaucoma related blindness.
###end article-title 101
###begin article-title 102
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Primary role of CYP1B1 in Indian juvenile-onset POAG patients.
###end article-title 102
###begin article-title 103
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Garchon HJ. CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma.
###end article-title 103
###begin article-title 104
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma.
###end article-title 104
###begin article-title 105
Molecular basis of Peters anomaly in Saudi Arabia.
###end article-title 105
###begin article-title 106
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Phenotypic heterogeneity of CYP1B1: mutations in a patient with Peters' anomaly.
###end article-title 106
###begin article-title 107
Novel CYP1B1 and known PAX6 mutations in anterior segment dysgenesis (ASD).
###end article-title 107
###begin article-title 108
Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene.
###end article-title 108
###begin article-title 109
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase.
###end article-title 109
###begin article-title 110
###xml 27 32 <span type="species:ncbi:9606">human</span>
Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism.
###end article-title 110
###begin article-title 111
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme.
###end article-title 111
###begin article-title 112
Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma.
###end article-title 112
###begin article-title 113
Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227.
###end article-title 113
###begin article-title 114
Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease.
###end article-title 114
###begin article-title 115
Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader.
###end article-title 115
###begin article-title 116
###xml 28 33 <span type="species:ncbi:9606">human</span>
Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2.
###end article-title 116
###begin article-title 117
###xml 38 43 <span type="species:ncbi:9606">human</span>
Isolation and characterization of the human cytochrome P450 CYP1B1 gene.
###end article-title 117
###begin article-title 118
Genotype and phenotype correlations in congenital glaucoma.
###end article-title 118
###begin article-title 119
Contribution of CYP1B1 mutations and founder effect to primary congenital glaucoma in Mexico.
###end article-title 119
###begin article-title 120
Cytochrome P4501B1 mutations cause only part of primary congenital glaucoma in Ecuador.
###end article-title 120
###begin article-title 121
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Mutational analysis of the Myocilin gene in patients with primary open-angle glaucoma in Morocco.
###end article-title 121
###begin article-title 122
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma.
###end article-title 122
###begin article-title 123
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Mutation spectrum of the CYP1B1 gene in Indian primary congenital glaucoma patients.
###end article-title 123
###begin article-title 124
Primary congenital glaucoma and Rieger's anomaly: extended haplotypes reveal founder effects for eight distinct CYP1B1 mutations.
###end article-title 124
###begin article-title 125
Structure conservation in cytochromes P450.
###end article-title 125
###begin article-title 126
Pivotal role of water in the mechanism of P450BM-3.
###end article-title 126
###begin article-title 127
###xml 84 90 <span type="species:ncbi:10090">murine</span>
Elkind MM. cDNA cloning, sequence analysis, and induction by aryl hydrocarbons of a murine cytochrome P450 gene, Cyp1b1.
###end article-title 127
###begin article-title 128
###xml 199 203 <span type="species:ncbi:10090">mice</span>
Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice.
###end article-title 128
###begin article-title 129
###xml 135 139 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Transplacental exposure to indole-3-carbinol induces sex-specific expression of CYP1A1 and CYP1B1 in the liver of Fischer 344 neonatal rats.
###end article-title 129
###begin article-title 130
###xml 58 63 <span type="species:ncbi:9606">human</span>
Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene.
###end article-title 130
###begin article-title 131
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
###end article-title 131
###begin article-title 132
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Correlations of genotype with phenotype in Indian patients with primary congenital glaucoma.
###end article-title 132
###begin article-title 133
Glaucoma-associated CYP1B1 mutations share similar haplotype backgrounds in POAG and PACG phenotypes.
###end article-title 133
###begin article-title 134
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Phenotype of cytochrome P4501B1 gene (CYP1B1) mutations in Japanese patients with primary congenital glaucoma.
###end article-title 134
###begin article-title 135
Surgical results of combined trabeculotomy-trabeculectomy for developmental glaucoma.
###end article-title 135
###begin article-title 136
###xml 22 29 <span type="species:ncbi:9606">infants</span>
Outcome of surgery on infants younger than 1 month with congenital glaucoma.
###end article-title 136
###begin article-title 137
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Identification of R368H as a predominant CYP1B1 allele causing primary congenital glaucoma in Indian patients.
###end article-title 137
###begin article-title 138
Primary congenital glaucoma: a novel single-nucleotide deletion and varying phenotypic expression for the 1,546-1,555dup mutation in the GLC3A (CYP1B1) gene in 2 families of different ethnic origin.
###end article-title 138

